ImmuCell develops, manufactures and markets animal health biologics for calf health and cattle productivity. Its primary product line, First Defense, uses colostrum-derived, orally delivered antibodies to provide Immediate Immunity against principal viral and bacterial causes of scours in newborn dairy and beef calves.
Company announcements commonly address preliminary product sales, unaudited financial results, manufacturing efficiency, commercial expansion, and the strategic focus on the First Defense franchise. Other recurring developments include board composition, committee structure, senior employment agreements, and updates tied to the paused investment in Re-Tain and related asset use.
ImmuCell Corporation (Nasdaq: ICCC) announced its preliminary, unaudited sales results for Q3 2020, revealing a 25% increase in product sales to $3.7 million compared to Q3 2019. For the nine-month period, sales rose 15% to $11.6 million. The company has significantly reduced its order backlog to $130,000 as of September 30, 2020. Management highlights continued growth driven by the Tri-Shield First Defense® product, which provides immediate immunity for calves. Future expansions in manufacturing capacity are expected, despite some COVID-19 related delays.
ImmuCell Corporation (Nasdaq: ICCC) announced its Q2 2020 financial results, reporting a 9% increase in product sales to $3 million compared to Q2 2019. For the six-month period, sales rose 11% to $7.9 million. Despite these gains, the company faced a net loss of $766,000, or $0.11 per share, compared to a loss of $627,000 in the same quarter last year. Gross margins declined to 43% from 46% year-over-year. However, cash reserves increased to $9.6 million, and the backlog of orders was reduced to approximately $945,000 as of June 30, 2020.
ImmuCell Corporation (Nasdaq: ICCC) plans to report its unaudited financial results for the second quarter ending June 30, 2020, on August 12, 2020. A conference call will be held the following morning, August 13, 2020, at 9:00 AM ET to discuss the results.
Investors can access the call by dialing (844) 855-9502 (toll-free) or (412) 317-5499 (international). A replay will be available for seven days after the call. The company will also file its Quarterly Report on Form 10-Q on the same day.
ImmuCell Corporation (Nasdaq: ICCC) has secured a $500,000 subordinated loan from the Maine Technology Institute (MTI) aimed at enhancing its production capabilities. The interest-free loan for the initial two years supports the expansion of the First Defense® product line and the development of Re-Tain™, which aims to offer a novel treatment for subclinical mastitis. This funding is critical for moving forward with the company's growth plans, including increasing annual production capacity from $18 million to $27 million. The company has also recently completed facility renovations to accommodate this expansion.
ImmuCell Corporation (Nasdaq: ICCC) announced a virtual format for its 2020 Annual Meeting of Stockholders due to the COVID-19 pandemic, scheduled for June 10 at 3:00 PM ET. Stockholders can participate via a dial-in conference call or an audio webcast. Those wishing to vote at the meeting must contact the company beforehand. Additionally, a conference call reviewing Q1 2020 financial results will take place on May 14 at 9:00 AM ET. The company emphasized the importance of stockholders voting via proxy ahead of the meeting. More details are available on their website.
ImmuCell Corporation (Nasdaq: ICCC) reported a 11% increase in product sales to $4.9 million for Q1 2020, compared to the same period in 2019. The First Defense® product line saw a 16% increase in sales. However, the company experienced a net loss of $122,000, or $0.02 per share, in contrast to a net income of $145,000, or $0.03 per share, in Q1 2019. A significant backlog of orders reached $1.4 million due to increased demand. Management is completing a facility expansion to boost production capacity from $18 million to $27 million.